A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab
A systematic review of the effectiveness of adalimumab
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Cochrane Library (CENTRAL)<br />
2005 Issue 1<br />
#1 rheumatoid NEXT arthritis in All Fields in<br />
all products<br />
#2 MeSH descriptor Arthritis, Rheumatoid, this<br />
term only in MeSH products<br />
#3 (#1 OR #2)<br />
#4 "tumor necrosis factor*" in All Fields in all<br />
products<br />
#5 "tumour necrosis factor*" in All Fields in all<br />
products<br />
#6 MeSH descriptor Receptors, Tumor Necrosis<br />
Factor, this term only in MeSH products<br />
#7 "anti tnf" in All Fields in all products<br />
#8 antitnf in All Fields in all products<br />
#9 infliximab in All Fields in all products<br />
#10 remicade in All Fields in all products<br />
#11 enbrel in All Fields in all products<br />
#12 etanercept in All Fields in all products<br />
#13 <strong>adalimumab</strong> in All Fields in all products<br />
#14 humira in All Fields in all products<br />
#15 (#4 OR #5 OR #6 OR #7 OR #8 OR #9<br />
OR #10 OR #11 OR #12 OR #13 OR #14)<br />
#16 (#3 AND #15)<br />
Ovid MEDLINE(R)<br />
1966 to February week 2 2005<br />
1 arthritis rheumatoid/<br />
2 tumo?r necrosis factor.mp.<br />
3 exp receptors tumor necrosis factor/<br />
4 anti TNF.mp.<br />
5 infliximab.mp.<br />
6 remicade.mp.<br />
7 enbrel.mp.<br />
8 etanercept.mp.<br />
9 or/2-8<br />
10 rheumatoid arthritis.mp.<br />
11 1 or 10<br />
12 9 and 11<br />
13 randomized controlled trial.pt.<br />
14 controlled clinical trial.pt.<br />
15 randomized controlled trials.sh.<br />
16 random allocation.sh.<br />
17 double blind method.sh.<br />
18 single blind method.sh.<br />
Appendix 2<br />
Health Technology Assessment 2006; Vol. 10: No. 42<br />
Searches: clinical <strong>effectiveness</strong><br />
© Queen’s Printer and Controller <strong>of</strong> HMSO 2006. All rights reserved.<br />
19 or/13-18<br />
20 (animals not human).sh.<br />
21 19 not 20<br />
22 clinical trial.pt.<br />
23 exp clinical trials/<br />
24 (clin$ adj25 trial$).ti,ab.<br />
25 ((singl$ or doubl$ or trebl$ or tripl$) adj25<br />
(blind$ or mask$)).ti,ab.<br />
26 placebo$.ti,ab.<br />
27 random$.ti,ab.<br />
28 placebos.sh.<br />
29 research design.sh.<br />
30 or/22-29<br />
31 30 not 20<br />
32 31 not 21<br />
33 21 or 32<br />
34 12 and 33<br />
35 limit 34 to yr=2001 - 2005<br />
36 <strong>adalimumab</strong>.mp.<br />
37 humira.mp.<br />
38 or/36-37<br />
39 1 and 38 and 33<br />
40 35 or 39<br />
EMBASE (Ovid)<br />
1980 to week 8 2005<br />
1 arthritis rheumatoid/<br />
2 tumo?r necrosis factor.mp.<br />
3 exp receptors tumor necrosis factor/<br />
4 anti TNF.mp.<br />
5 infliximab.mp.<br />
6 remicade.mp.<br />
7 enbrel.mp.<br />
8 etanercept.mp.<br />
9 or/2-8<br />
10 rheumatoid arthritis.mp.<br />
11 1 or 10<br />
12 9 and 11<br />
13 <strong>adalimumab</strong>.mp.<br />
14 humira.mp.<br />
15 or/13-14<br />
16 randomized controlled trial/<br />
17 exp clinical trial/<br />
18 exp controlled study/<br />
19 double blind procedure/<br />
20 randomization/<br />
21 placebo/<br />
141